What development phase is BOPINDOLOL in?

BOPINDOLOL is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

BOPINDOLOL

FDA-approved active Small molecule Quality 15/100

At a glance

Generic name	BOPINDOLOL
Drug class	bopindolol
Target	5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BOPINDOLOL CI brief — competitive landscape report
BOPINDOLOL updates RSS · CI watch RSS